Biochemické nástroje k cílení imunomodulačního receptoru CD73

Poukarová, Magdalena

New approaches to cancer treatment are investigated because cancer remains one of the most abundant causes of death. One of the promising fields of oncology is immunotherapy, which is based on the activation of immunity to eliminate malignant cells. Several immunotherapy drugs have already been approved and are being used; however, only a part of patients responds with the desired efficiency. In recent years, ecto-5'-nucleotidase CD73 emerged as a potential new target of immunotherapy. The expression of this GPI-anchored enzyme at the extracellular membrane is significantly up-regulated tumour cells and in immune cells of the tumour microenvironment. CD73 catalyses the hydrolysis of AMP to immunosuppressive adenosine, therefore contributing to the immunosuppressive environment in the tumour and participating in resistance to immunotherapy. CD73 appears to be a promising target for a combination treatment to improve the effect of other immunotherapy drugs. So far, several clinical trials of CD73 antibodies and small-molecule inhibitors have been conducted. This diploma thesis describes the development of new biochemical tools for CD73. DNA- linked Inhibitor ANtibody Assay (DIANA), a sensitive method that enables the measurement of the binding affinity of a small-molecule inhibitor to a protein, was...

guest :: login Digital Repository
		Search		Submit		Help		About